• Home
  • Investors
  • Corporate Governance
  • Board Structure

Board Structure

Composition of the BOD

The board of directors is composed of seven members consisting of three internal directors and four indep endent directors. Independent directors are independent having no ties to the company through transactions or as former employees or inside directors.

  • President & CEO - Dr. Tae Han Kim
    President & CEO
    Dr. Tae Han Kim
    • President & CEO,
      Samsung Biologics
      (2011-Present)
    • Full Member,
      The National Academy of
      Engineering of Korea
      (2013-Present)
    President & CEO / Dr. Tae Han Kim
  • Senior Vice President & Managing Director / Dong joong Kim
    Senior Vice President
    & Managing Director
    Dong joong Kim
    • Senior Vice President & Managing
      Director, Business Resources Innovation Center, Samsung Biologics
      (2014-Present)
    • Head of Planning Support Team,
      Production Technology Institute,
      Samsung Electronics
      (2013-2014)
    Senior Vice President & Managing Director / Dong joong Kim
  • Executive Vice President / John Rim
    Executive Vice President
    John Rim
    • Executive Vice President, CMO2 Center, Samsung Biologics (2018-Present)
    • Roche, Global Product Development Procurement, VP (2014-2018)
    • Roche, CFO Global Product Development, VP (2010-2013)
    Executive Vice President / John Rim
  • Independent director / Seok Woo Jeong
    Independent director
    Seok Woo Jeong
    • Independent Director,
      Samsung Biologics
      (2016-Present)
    • Professor, Department of Business Administration, Korea University Business School (1997-Present)
    • Non-standing Member,
      Korea Accounting Institute
      (2016-Present)
    Independent director / Seok Woo Jeong
  • Independent director / Soon Jo Kwon
    Independent director
    Soon Jo Kwon
    • Independent Director,
      Samsung Biologics
      (2016-Present)
    • Professor, Department of BioLogical Engineering, Inha University(2013-Present)
    • Chairman, International
      Cooperation Committee, Institute of Biological Engineering (IBE)
      (2011-2013)
    Independent director / Soon Jo Kwon
  • Independent director / Kun Nyoung Huh
    Independent Director
    Kun Nyoung Huh
    • Independent Director,
      Samsung Biologics
      (2019-Present)
    • Advisor, Pyeong An Lawfirm(2019-Present)
    • Presiding Judge,
      Seoul Central District Court
      (2004-2007)
    Independent director / Kun Nyoung Huh
  • INDEPENDENT DIRECTOR / Eunice Kyunghee Kim
    Independent Director
    Eunice Kyunghee Kim
    • Independent Director, Samsung Biologics (2020-Present)
    • Professor at Law School of Ewha Women's University (2010-Present)
    • Vice president of International Association of Korean Lawyers (IAKL) (2008-Present)
    • Compliance officer of executive vice president & Head of Legal Affairs at Hana Financial Group, Inc. (2008-2010)
    Independent director / Eunice Kyunghee Kim

Appointment of Directors

Members of the board of directors are elected through a resolution of the general meeting of shareholders under the company’s articles of incorporation. Incumbent members may be reelected after the expiration of their terms.

  • Samsung Biologics shall have at least three but no more than ten directors and such directors shall be appointed at the general meeting of shareholders; provided, however, that at least three independent directors shall be appointed and the number of the independent directors shall account for at last a majority of the total number of directors.
  • A resolution for the election of directors shall be adopted by the affirmative votes of a majority of the shareholders present at the meeting, which shall also be at least 1/4 of the total number of issued and outstanding shares.
  • Any vacancy in the office of directors shall be filled at a general meeting of shareholders; provided, however, that if the number of directors does not fall below the number prescribed in Paragraph 1 of Article 29 in the Articles of Incorporation and there is no difficulty in the administration of business, the foregoing shall not be applicable.

Term of Office of Director

The term of office of directors shall end at the close of the ordinary general meeting of shareholders convened in respect to the last fiscal year within three years from their appointment.

Chairperson

The chairperson of the board of directors shall be appointed among the directors by a resolution of the board of directors.

Resolution of the BOD

The resolution of the board of directors shall be adopted in the attendance of a majority of the directors in the office and by the affirmative votes of a majority of the directors present at the meeting; provided, however, that a resolution of the board of directors on matters stipulated under Article 397-2 (Prohibition of Use of Corporate Opportunities and Assets) and Article 398 (Self-Dealing between Directors, etc. and the Company) of the Commercial Code shall be adopted by the affirmative votes of at least 2/3 of the directors in office.

Independence of Independent Directors

The Independent Director Candidate Nomination Committee shall nominate the candidates for the independent directors among persons who meet qualification requirements stipulated in the relevant laws and regulations, including the Commercial Code, etc.

  • An independent director shall be one with professional knowledge or sufficient experience in management, economics, accounting, law or relevant technology and duly qualified under the relevant law. He or she shall not be a current employee or director or a previous employee or director of the company or its affiliate (as stipulated in the Monopoly Regulation and Fair Trade Act) within the past two years, a major shareholder of the company or one with a special relationship with a major shareholder.

Operation / Duties

The board of directors shall be divided into an ordinary and extraordinary board.
In principle the chairperson convenes the board of directors meeting, and if it is deemed necessary for administration of business, any director may convene the board of directors meeting with the consent of the chairperson.

BOD Operation Rules PDF Download PDF doesn't open in Chrome

Meetings of the BOD

The board of directors shall be divided into an ordinary and extraordinary board.

  • Ordinary Board of Directors : The meeting of ordinary board of directors is held once a quarter. The chairperson of the board of directors shall set the date and call for the meeting.
  • Extraordinary Board of Directors : The meeting of extraordinary board of directors may be held from time to time as required.

Convening of BOD Meeting

In principle the chairperson convenes the board of directors meeting, and if it is deemed necessary for administration of business, any director may convene the board of directors meeting with the consent of the chairperson.

  • Procedure : The chairperson shall set a date and time of the meeting of the board of directors and give a notice to each director no later than twenty four hours prior to the meeting in writing, electronic document, or orally; provided, however, that such notice may be waived with the unanimous consent of all directors.

Resolution of the BOD

The resolution of the board of directors shall be adopted in the attendance of a majority of the directors in office and by the affirmative votes of a majority of the directors present at the meeting.

  • The board of directors may allow all or a part of the directors who do not attend a meeting in person to participate in a resolution through communication that concurrently transmits and receives voices of all directors. In this case, such director shall be deemed to have attended the board of directors meeting in person.
  • A director with his or her own interests in a resolution of the board of directors shall not be allowed to participate in voting.

BOD Operation Rules

Article 1Purpose
Article 2Scope of Applications
  • With respect to matters pertaining to the BOD, these rules and regulations shall apply unless those stipulated otherwise in the relevant laws or the AOI.
Article 3Authority
  • The BOD shall deliberate and resolve matters stipulated in the relevant laws or the AOI, matters authorized by the general meeting of shareholders, and important issues concerning basic policies and execution of business related to the management of the Company.
  • The BOD shall supervise the directors’ execution of duty.
  • When it is determined that a director has violated a provision of the laws or the AOI in performing his/her duties, or performed such duties in a substantially improper manner, or the BOD recognizes that there is a concern that such director will perform his/ her duties in a substantially improper manner, the BOD may request such director to submit relevant data, cooperate on investigation, and/or provide explanation.
  • If any of the events in Paragraph 3 occurs, the BOD may require the relevant director to suspend or change the performance of relevant duties.
  • Any director may request the representative director to report performance of other directors or employees to the BOD.
Article 4Composition
  • The BOD shall be comprised of all directors.
  • The term of office of a director shall expire at the close of the ordinary general meeting of shareholders held for the third fiscal period from the inauguration of the applicable director.
Article 5Chairperson
  • The chairperson of the BOD shall be appointed among the directors by a resolution of the BOD.
  • The term of office of the chairperson shall end at the expiration of the term of office of the applicable director.
  • When the chairperson is unable to perform his/her duties, the director that was first appointed among all of the directors of the BOD shall act as the chairperson; provided, however, that if two (2) or more directors were appointed on the same date, the most senior director shall act as the chairperson.
Article 6Convening of BOD Meeting
  • The meetings of the BOD shall be either ordinary meetings or extraordinary meetings.
  • Ordinary meetings of the BOD shall, in principle, be convened once each quarter.
  • Extraordinary meetings of the BOD shall be convened on an ad-hoc basis when deemed necessary.
  • The chairperson of the BOD shall set a date and time of the meeting of the BOD, and provide written, electronic, or oral notice to each director no later than 24 hours in advance of such meeting; provided, however, that such convocation procedure may be omitted upon unanimous consent of the directors.
  • If it is deemed necessary for carrying out the business of the Company, any director may convene a meeting of the BOD upon the consent of the chairperson. In this case, the provisions in Paragraph 4 above shall apply mutatis mutandis.
Article 7Method of Resolution
  • Unless stipulated otherwise in the relevant laws and regulations, the BOD resolutions shall be done in accordance with Paragraphs 1 through 3 of Article 38 of the AOI.
  • Unless stipulated otherwise in the relevant laws and regulations, the number of directors who cannot exercise his/her vote in accordance with Article 38, Paragraph 3 of the AOI shall not be included in the number of directors present at the meeting.
Article 8Agenda
  • The following matters shall be resolved by the BOD:
    • 1.Convening of the general meeting of shareholders and matters for resolution to be submitted thereto
      【Mandatory agenda items set forth in the relevant laws/regulations and the AOI】
      • 1)Convening of the general meeting of shareholders
      • 2)Approval of financial statements
      • 3)Approval of annual report
      • 4)Distribution of profits
      • 5)Amendment to the AOI
      • 6)Capital reduction
      • 7)Dissolution, amalgamation, spin-off, merger through spin-off, continuation of company (Article 519 of the Commercial Code)
      • 8)Assignment of the businesses of the Company in whole or in material part; acquisition in whole or in part of another company’s business having a material impact on the business of the Company
      • 9)Lease or entrustment of management business in whole; execution of contract where all profits and losses are shared with a 3rd party (each a “Shared Contract”); execution, amendment, or termination of another contract that is commensurate to a Shared Contract
      • 10)Ex-post incorporation
      • 11)Appointment and dismissal of directors
      • 12)Remuneration of directors
      • 13)Issuance of shares at less-than-face value
      • 14)Acquisition of treasury shares
      • 15)Decision on stock dividends
      • 16)Stock-split and stock-consolidation of shares
      • 17)Waiver of a director’s liability toward the Company upon unanimous consent of the shareholders
      • 18)Redemption of shares
      • 19)Total share swap
      • 20)Total share transfer
      • 21)Granting of stock options
      • 22)Other agenda items to be submitted to the general meeting of shareholders and material issues concerning shares
    • 2.Matters pertaining to management
      【Mandatory agenda items set forth in the relevant laws/regulations and the AOI】
      • 1)Decision on short form merger, short form merger through spin-off, small-scale mergers, and small-scale merger through spin-off
      • 2)Execution and reporting of asset revaluation
      【Other important matters pertaining to the management of the Company】
      • 1)Establishment and revision of basic policies on the management of the Company
    • 3.Matters pertaining to finance
      【Mandatory agenda items set forth in the relevant laws/regulations and the AOI】
      • 1)Disposition or redemption of treasury shares
      • 2)Issuance of new shares
      • 3)Issuance of corporate bonds, convertible bonds, or bonds with warrants
      • 4)Capitalization of reserves
      • 5)Allocation of new shares to a 3rd party
      • 6)Distribution of interim dividends
      • 7)Transaction with a “specially-related party” as set forth in the Commercial Code or large-scale transaction for a “specially-related party”
      • 8)Handling of forfeited shares in case of capitalization by issuing new shares
      【Other important matters pertaining to finance】
      • 1)Foreign direct investment valued at 2.5% or more of the equity capital of the Company
      • 2)Listing of shares or depository certificates in a foreign stock exchange
      • 3)Borrowing valued at 2.5% or more of the equity capital of the Company
      • 4)Acquisition or waiver of debt valued at 2.5% or more of the equity capital of the Company per transaction
      • 5)Offering of security or guarantee of debt valued at 2.5% or more of the equity capital of the Company per transaction
      • 6)Donation or sponsorship valued at KRW 100 million or more
      • 7)Other important financial matters to be submitted to the BOD
    • 4.Matters pertaining to directors, the BOD, committees, etc.
      【Mandatory agenda items set forth in the relevant laws/regulations and the AOI】
      • 1)Appointment of the representative director
      • 2)Appointment of the chairperson of the BOD in case the representative director is unable to serve as the chairperson
      • 3)Establishment and operation of a committee(s) within the BOD, appointment and dismissal of a committee member
      • 4)Approval of a director serving as a concurrent director at another company that competes with or operates in the same industry as the Company and approval of transaction between a director, etc., and the Company
      • 5)Re-resolution of an agenda item for resolution by a committee within the BOD
      • 6)Appointment or dismissal of a director from a specific position or duty
      【Other important matters pertaining to directors, the BOD, committees, etc.】
      • 1)Enforcement or nullification of the Rules and Regulations of the Board of Directors or the rules and regulations of committees within the BOD (operational guidelines)
    • 5.Others
      • 1)Other matters set forth in the relevant laws and regulations or the AOI, authorized and delegated by the general meeting of shareholders, or deemed necessary by the representative director
  • The following matters shall be reported to the BOD:
    • 1.Matters that have been delegated to a committee(s) within the BOD and how such matters were decided / resolved
    • 2.Matters for which the Audit Committee has determined that a director has or there is a concern that a director may violate the relevant laws or the AOI
    • 3.Other matters pertaining to the execution of matters that are considered important to the operations of the Company
Article 9Delegation of Authority
  • Unless stipulated otherwise in the relevant laws and regulations or the AOI, the representative director or a committee authorized by the BOD under Article 10 may be delegated with the authority to make decisions on matters that require a resolution of the BOD.
Article 10Committees under BOD
  • Committees within the BOD shall be subject to Article 37 of the AOI; provided, however, that with respect to the Audit Committee, Chapter 6 (Audit Committee) of the AOI shall first apply.
  • The Management Committee shall operate in compliance with the rules and resolutions of the BOD, and in addition, deliberate on and resolve matters delegated by the BOD from time to time.
  • Unless they are in conflict with Paragraph 1 of this Article 10 and the rules of applicable committee within the BOD, Article 38 of the AOI shall apply mutatis mutandis to the committee(s) within the BOD. In such provisions of the AOI, “BOD” shall mean applicable “committee within the BOD” and “Director” shall mean a “member of such committee.”
  • Notwithstanding anything stated in Paragraph 3 of Article 10, matters set forth in Article 397-2 (Restriction on Abuse of Corporate Opportunities and Assets of the Company) and Article 398 (Transactions between Directors, Etc., and the Company) of the Commercial Code shall be adopted by two-thirds or more of the registered directors of the BOD.
Article 11Counsel of Relevant Persons
  • In deliberating on an agenda item, the BOD may invite a relevant officer or employee of the Company or a third party to attend the BOD meeting and explain the agenda item or provide his/her opinion.
  • The BOD may, at the cost of the Company, resolve to engage an expert or other similar individual to consult on a particular agenda item, if it finds such a service necessary.
Article 12Meeting Minutes
  • Meeting minutes shall be prepared for BOD meetings and meetings of any committee within the BOD, and such meeting minutes shall set forth the agenda, proceedings of the meeting, results, objecting party and reason(s) for objection, and be affixed with the seal impressions of or signed by the directors present at the meeting.
Article 13Ratification
  • If an issue is urgent, and there is insufficient time to convene a meeting of the BOD, so long as and to the extent it does not violate the relevant laws and regulations, the representative director shall perform the necessary action and convene a meeting of the BOD after the fact where he/she shall report the progress of such action and obtain the BOD’s ratification.
Article 14Secretary
  • The BOD shall have a secretary who shall be appointed by the chairperson.
  • The chairperson of the BOD shall instruct and supervise the secretary. The secretary shall assist each director of the BOD and administer the overall operations of the BOD.
Article 15Expenses
  • Expenses necessary for meetings and other operations shall be borne by the Company.
Article 16Enactment and Nullification of the Rules
  • These Rules shall be enacted and nullified by a resolution of the BOD.
Addendum
  • Article 1 (Effective Date)
  • These Rules shall become effective on August 10, 2016.

Major Agenda items

1. A director with his or her own interests in a resolution of the board of directors shall not be allowed to participate in voting.

  • Convening of the general meeting of shareholders
  • Approval of financial statements
  • Approval of annual report
  • Amendment to the AOI
  • Dissolution, amalgamation, continuation of company
  • Assignment of the businesses of the company in whole or in material part; acquisition in whole or in part of another company’s business having a material impact on the business of the company.
  • Appointment and dismissal of directors
  • Remuneration of directors, etc.

2. Matters pertaining to management

  • Matters pertaining to management
  • Enforcement or nullification of the Rules and Regulations of the Board of Directors or the rules and regulations of committees within the BOD

3. Matters pertaining to finance

  • Disposition or redemption of treasury shares
  • issuance of new shares
  • Issuance of corporate bonds, convertible bonds, or bonds with warrants
  • Foreign direct investment, borrowing, acquisition or waiver of debt, offering of security or guarantee of debt, etc.
  • Transaction with a “specially-related party” as set forth in the Commercial Code or large-scale transaction for a “specially-related party”, etc.
  • Donation or sponsorship

4. Matters pertaining to directors, the BOD, committees, etc.

  • Appointment of the representative director
  • Appointment of the chairperson of the BOD
  • Approval of a director serving as a concurrent director at another company that competes with or operates in the same industry as the Samsung iologics and approval of transaction between a director, etc., and Samsung Biologics
  • Appoint or dismissal of a director from a specific position or duty

5. Others

  • Other matters set forth in the relevant laws and regulations or the AOI, authorized and delegatedby the general meeting of shareholders, or deemed necessary by the representative director

Activity of the BOD

Activity of the BOD includes the status of the board of directors' activities such as appointment, commissioning, approval, participation, decision, revision, enforcement, reporting and issuance.

2019

2019 Activity of the BOD - Date, Agenda, Result, Attendance
Date Agenda Result Attendance
DEC. 16, 2019 (Reported) FY2019 Incentive payment status - 5/5
1. Approval of transactions with major shareholder Approved
2. Approval of transactions with related parties Approved
3. Joining a financial instrument of Samsung Securities Approved
4. Payment of retirement pension Approved
OCT. 23, 2019 (Reported) FY2019 3Q earnings report - 5/5
SEP. 11, 2019 (Reported) Discussions on the creation of a support organization in the Audit Committee - 5/5
JUL. 23, 2019 (Reported) FY2019 half year earnings report - 5/5
1. Approval of FY2018 financial statements corrections -
APR. 24, 2019 (Reported) FY2019 1st quarter earnings report - 5/5
1. Approval of transactions with related parties Approved
MAR. 22, 2019 1. Appointment of members of committees within the BOD Approved 5/5
2. Setting the remuneration of directors Approved
3. Joining a financial instrument of Samsung Securities Approved
4. Approval of transactions with related parties Approved
FEB. 27, 2019 (Report) Reporting the operation status of internal accounting management system - 5/5
(Report) Evaluation and audit report of the internal accounting management system -
(Report) 2019 Incentive Payment Report -
(Report) Evaluation and report of 2018 Compliance -
1. Decision to convene the 8th(FY2018) AGM -
JAN. 31, 2019 1. Approval of FY2018 financial statements and annual business report - 5/5
2. Approval of revision of the operation regulations of audit committee Approved
3. Approval of revision of internal accounting control system regulations Approved
4. Addition of New Business Place Approved
5. Approval of transactions with major shareholders Approved
DEC. 16, 2019 Activity of the BOD - Date, Attendance, Agenda, Result,
DEC. 16, 2019 Attendance 5/5
Agenda (Reported) FY2019 Incentive payment status
Result -
Agenda 1. Approval of transactions with major shareholder
Result Approved
Agenda 2. Approval of transactions with related parties
Result Approved
Agenda 3. Joining a financial instrument of Samsung Securities
Result Approved
Agenda 4. Payment of retirement pension
Result Approved
OCT. 23, 2019 Activity of the BOD - Date, Attendance, Agenda, Result,
OCT. 23, 2019 Attendance 5/5
Agenda (Reported) FY2019 3Q earnings report
SEP. 11, 2019 Activity of the BOD - Date, Attendance, Agenda, Result,
SEP. 11, 2019 Attendance 5/5
Agenda (Reported) Discussions on the creation of a support organization in the Audit Committee
Result -
JUL. 23, 2019 Activity of the BOD - Date, Attendance, Agenda, Result,
JUL. 23, 2019 Attendance 5/5
Agenda (Reported) FY2019 half year earnings report
Result -
Agenda 1. Approval of FY2018 financial statements corrections
Result -
APR. 24, 2019 Activity of the BOD - Date, Attendance, Agenda, Result,
APR. 24, 2019 Attendance 5/5
Agenda (Reported) FY2019 1st quarter earnings report
Result -
Agenda 1. Approval of transactions with related parties
Result Approved
MAR. 22, 2019 Activity of the BOD - Date, Attendance, Agenda, Result,
MAR. 22, 2019 Attendance 5/5
Agenda 1. Appointment of members of committees within the BOD
Result Approved
Agenda 2. Setting the remuneration of directors
Result Approved
Agenda 3. Joining a financial instrument of Samsung Securities
Result Approved
Agenda 4. Approval of transactions with related parties
Result Approved
FEB. 27, 2019 Activity of the BOD - Date, Attendance, Agenda, Result,
FEB. 27, 2019 Attendance 5/5
Agenda (Report) Reporting the operation status of internal accounting management system
Result -
Agenda (Report) Evaluation and audit report of the internal accounting management system
Result -
Agenda (Report) 2019 Incentive Payment Report
Result -
Agenda (Report) Evaluation and report of 2018 Compliance
Result -
Agenda 1. Decision to convene the 8th(FY2018) AGM
Result Approved
JAN. 31, 2019 Activity of the BOD - Date, Attendance, Agenda, Result,
JAN. 31, 2019 Attendance 5/5
Agenda 1. Approval of FY2018 financial statements and annual business report
Result Approved
Agenda 2. Approval of revision of the operation regulations of audit committee
Result Approved
Agenda 3. Approval of revision of internal accounting control system regulations
Result Approved
Agenda 4. Addition of New Business Place
Result Approved
Agenda 5. Approval of transactions with major shareholders
Result Approved

2018

2018 Activity of the BOD - Date, Agenda, Result, Attendance
Date Agenda Result Attendance
DEC. 24, 2018 1. Approval of transactions with major shareholders Approved 5/5
2. Approval of transactions with related parties Approved
3. Payment of retirement pension Approved
4. Revision of the in-house trade committee’s operation provisions Approved
OCT. 23, 2018 (Reported Item) FY2018 3rd quarter earnings report - 5/5
1. Time deposits of Samsung Securities Co., Ltd. Approved
2. Investments in subsidiaries Approved
OCT. 04, 2018 (Reported Item) Report on Major Management Issues - 5/5
JUL. 23, 2018 (Reported Item) FY2018 1st half year earnings report - 5/5
JUN. 28, 2018 (Reported Item) Report on Major Management Issues - 5/5
APR. 24, 2018 (Reported Item) FY2018 1st quarter earnings report - 5/5
1. Issue of Corporate bond Approved
2. Approval of trading with controlling shareholder Approved
MAR. 22, 2018 1. Setting the remuneration of directors Approved 5/5
FEB. 28, 2018 (Reported Item) Report on the internal accounting management system - 5/5
1. Approval of FY2017 financial statements and annual business report Approved
2. Decision to convene the 7th(FY2017) AGM Approved
JAN. 31, 2018 (Reported Item) Performance bonus of FY2017 for key objectives - 5/5
1. Approval of FY2017 financial statements and annual business report Approved
2. Revision of the operation regulations of the independent director referral committee Approved
DEC. 24, 2018 Activity of the BOD - Date, Attendance, Agenda, Result,
DEC. 24, 2018 Attendance 5/5
Agenda 1. Approval of transactions with major shareholders
Result Approved
Agenda 2. Approval of transactions with related parties
Result Approved
Agenda 3. Payment of retirement pension
Result Approved
Agenda 4. Revision of the in-house trade committee’s operation provisions
Result Approved
OCT. 23, 2018 Activity of the BOD - Date, Attendance, Agenda, Result,
OCT. 23, 2018 Attendance 5/5
Agenda (Reported Item) FY2018 3rd quarter earnings report
Result -
Agenda 1. Time deposits of Samsung Securities Co., Ltd.
Result Approved
Agenda 2. Investments in subsidiaries
Result Approved
OCT. 04, 2018 Activity of the BOD - Date, Attendance, Agenda, Result,
OCT. 04, 2018 Attendance 5/5
Agenda (Reported Item) Report on Major Management Issues
Result -
JUL. 23, 2018 Activity of the BOD - Date, Attendance, Agenda, Result,
JUL. 23, 2018 Attendance 5/5
Agenda (Reported Item) FY2018 1st half year earnings report
Result -
JUN. 28, 2018 Activity of the BOD - Date, Attendance, Agenda, Result,
JUL. 28, 2018 Attendance 5/5
Agenda (Reported Item) Report on Major Management Issues
Result -
APR. 24, 2018 Activity of the BOD - Date, Attendance, Agenda, Result,
APR. 24, 2018 Attendance 5/5
Agenda (Reported Item) FY2018 1st quarter earnings report
Result -
Agenda 1. Issue of Corporate bond
Result Approved
Agenda 2. Approval of trading with controlling shareholder
Result Approved
MAR. 22, 2018 Activity of the BOD - Date, Attendance, Agenda, Result,
MAR. 22, 2018 Attendance 5/5
Agenda 1. Setting the remuneration of directors
Result Approved
FEB. 28, 2018 Activity of the BOD - Date, Attendance, Agenda, Result,
FEB. 28, 2018 Attendance 5/5
Agenda (Reported Item) Report on the internal accounting management system
Result -
Agenda 1. Approval of FY2017 financial statements and annual business report
Result Approved
Agenda 2. Decision to convene the 7th(FY2017) AGM
Result Approved
JAN. 31, 2018 Activity of the BOD - Date, Attendance, Agenda, Result,
JAN. 31, 2018 Attendance 5/5
Agenda (Reported Item) Performance bonus of FY2017 for key objectives
Result -
Agenda 1. Approval of FY2017 financial statements and annual business report
Result Approved
Agenda 2. Revision of the operation regulations of the independent director referral committee
Result Approved

2017

2017 Activity of the BOD - Date, Agenda, Result, Attendance
Date Agenda Result Attendance
JUL. 24, 2017 Report on financial results concerning 2Q/2017 - 5/5
1. Approval of transactions with major shareholders Approved
JUL. 30, 2017 Report on result of corporate appraisal of the company in the first half of 2017 - 5/5
MAY. 18, 2017 Report on status of operation of the company’s evaluation/remuneration system - 5/5
1. Approval of transactions with major shareholders Approved
APR. 25, 2017 Report on financial results concerning 1Q/2017 - 5/5
MAR. 24, 2017 1. Election of the representative director and entrustment of business to directors Approved 5/5
2. Appointment of the chairperson of the board of directors Approved
3. Appointment of members of the committees of the board of directors Approved
4. Execution of limit of directors’ remuneration Approved
5. Revision of the rules and regulations of the board of directors Approved
FEB. 27, 2017 1. Convening of the general meeting of shareholders and decision on purpose of the meeting Approved 5/5
2. Approval of transactions with major shareholders Approved
JAN. 24, 2017 1. Convening of the general meeting of shareholders and decision on purpose of the meeting Approved 5/5
JUL. 24, 2017 Activity of the BOD - Date, Attendance, Agenda, Result,
JUL. 24, 2017 Attendance 5/5
Agenda Report on financial results concerning 2Q/2017
Result -
Agenda 1. Approval of transactions with major shareholders
Result Approved
JUL. 30, 2017 Activity of the BOD - Date, Attendance, Agenda, Result,
JUL. 30, 2017 Attendance 5/5
Agenda Report on result of corporate appraisal of the company in the first half of 2017
Result -
MAY. 18, 2017 Activity of the BOD - Date, Attendance, Agenda, Result,
MAY. 18, 2017 Attendance 5/5
Agenda Report on status of operation of the company’s evaluation/remuneration system
Result -
Agenda 1. Approval of transactions with major shareholders
Result Approved
APR. 25, 2017 Activity of the BOD - Date, Attendance, Agenda, Result,
APR. 25, 2017 Attendance 5/5
Agenda Report on financial results concerning 1Q/2017
Result -
MAR. 24, 2017 Activity of the BOD - Date, Attendance, Agenda, Result,
MAR. 24, 2017 Attendance 5/5
Agenda 1. Election of the representative director and entrustment of business to directors
Result Approved
Agenda 2. Appointment of the chairperson of the board of directors
Result Approved
Agenda 3. Appointment of members of the committees of the board of directors
Result Approved
Agenda 4. Execution of limit of directors’ remuneration
Result Approved
Agenda 5. Revision of the rules and regulations of the board of directors
Result Approved
FEB. 27, 2017 Activity of the BOD - Date, Attendance, Agenda, Result,
FEB. 27, 2017 Attendance 5/5
Agenda 1. Convening of the general meeting of shareholders and decision on purpose of the meeting
Result Approved
Agenda 2. Approval of transactions with major shareholders
Result Approved
JAN. 24, 2017 Activity of the BOD - Date, Attendance, Agenda, Result,
JAN. 24, 2017 Attendance 5/5
Agenda 1. Convening of the general meeting of shareholders and decision on purpose of the meeting
Result Approved

2016

2016 Activity of the BOD - Date, Agenda, Result, Attendance
Date Agenda Result Attendance
DEC. 13, 2016 1. Participation in Samsung Bioepis’ capital increase Approved 5/5
2. Participation in Archigen’s capital increase Approved
3. Approval of transactions with major shareholders Approved
4. Approval of transactions with specially related parties Approved
5. Subscription to retirement pension Approved
SEP. 29, 2016 1. Approval for issuance of new shares for IPO and for sales of old shares Approved 5/5
2. Approval of internal trading with specially related parties Approved
AUG. 10, 2016 1. Appointment of the chairperson of the board of directors Approved 5/5
2. Entrusting business to directors Approved
3. Appointment of the members of the committees of the board of directors Approved
4. Appointment of the compliance officer Approved
5. Appointment of the transfer agent Approved
DEC. 13, 2016 Activity of the BOD - Date, Attendance, Agenda, Result,
DEC. 13, 2016 Attendance 5/5
Agenda 1. Participation in Samsung Bioepis’ capital increase
Result Approved
Agenda 2. Participation in Archigen’s capital increase
Result Approved
Agenda 3. Approval of transactions with major shareholders
Result Approved
Agenda 4. Approval of transactions with specially related parties
Result Approved
Agenda 5. Subscription to retirement pension
Result Approved
SEP. 29, 2016 Activity of the BOD - Date, Attendance, Agenda, Result,
SEP. 29, 2016 Attendance 5/5
Agenda 1. Approval for issuance of new shares for IPO and for sales of old shares
Result Approved
Agenda 2. Approval of internal trading with specially related parties
Result Approved
AUG. 10, 2016 Activity of the BOD - Date, Attendance, Agenda, Result,
AUG. 10, 2016 Attendance 5/5
Agenda 1. Appointment of the chairperson of the board of directors
Result Approved
Agenda 2. Entrusting business to directors
Result Approved
Agenda 3. Appointment of the members of the committees of the board of directors
Result Approved
Agenda 4. Appointment of the compliance officer
Result Approved
Agenda 5. Appointment of the transfer agent
Result Approved

SITE MAP

close
close

Samsung Biologics
Privacy Policy

초점받기 링크
Effective Date: [30Dec2019]

This Privacy Policy illustrates how Samsung Biologics ("we", “our”, “us”) use and protect information you provide through your use of this website (the "Website") or our customer inquiry and recruitment services (collectively the “Services”).

Please read this Privacy Policy carefully and feel free to contact us if you have any questions, using the contact information provided in the Contact Us section below.

Information we may collect from you
1.Customer Inquiry

When you fill out the “Contact Us Form” on our Website, we may collect the following types of information:

  • Customer Inquiry information include Category, Information we may collect from you.
    Category Information we may collect from you
    Contact Us Mandatory Name, E-mail Address, Company Name, Occupation, Country, Areas of Interest, Inquiries/Comments
    Optional Any additional information you provide including but not limited to the job title
    Customer Inquiry information include Category, Information we may collect from you.
    Category Information we may collect from you
    Contact Us Mandatory Name, E-mail Address, Company Name, Occupation, Country, Areas of Interest, Inquiries/Comments
    Optional Any additional information you provide including but not limited to the job title

    Access log and website usage information collected through cookies. For more information about how we use cookies on our Website, please see our Cookie Policy.

2.Recruitment

When you submit your application via “TalentPool” on our Website, we may collect the following types of information:

  • Recruitment infomation include Category, Information we may collect from you.
    Category Information we may collect from you
    Talent Pool Mandatory Name, E-mail Address, Country, Areas of Interest, Resume
    Optional Any additional information you provide including but not limited to personal profiles on SNS
    Application Form
    (in Korean)
    Mandatory Name, Date of Birth, Address, E-mail, Contact Number,
    Education History (Name of School, Major, Enrollment Year/Month, Graduation Year/Month, Location), Employment History (Employment Period, Company, Job Title, Job Scope, Major Task), Language, Miscellaneous (Military Status, Reason for Exemption, Veteran Status)
    Optional Any additional information you provide including but not limited to research career, special qualifications and licenses, personal profiles on SNS.
    Recruitment infomation include Category, Information we may collect from you.
    Category Information we may collect from you
    Talent Pool Mandatory Name, E-mail Address, Country, Areas of Interest, Resume
    Optional Any additional information you provide including but not limited to personal profiles on SNS
    Application Form
    (in Korean)
    Mandatory Name, Date of Birth, Address, E-mail, Contact Number,
    Education History (Name of School, Major, Enrollment Year/Month, Graduation Year/Month, Location), Employment History (Employment Period, Company, Job Title, Job Scope, Major Task), Language, Miscellaneous (Military Status, Reason for Exemption, Veteran Status)
    Optional Any additional information you provide including but not limited to research career, special qualifications and licenses, personal profiles on SNS.

*No sensitive information will be collected.

How we use your information
1.Customer Inquiry

We may use the information we collect from you to conduct certain services or activities such as replying to inquiries, maintaining business records, and conducting market research.

2.Recruitment

In order to proceed with recruitment process and communicate status/result of job application(s).

Sharing information with third parties

We will not disclose your information to third parties for their marketing or business purposes without your consent. However, notwithstanding the above, we may disclose your information to the following entities for recruitment purposes:

  • Educational institutions in your application.
    Your information (name, date of birth, major, admission year, graduation year, etc.) may be disclosed to educational institutions named in your application.
  • Previous companies you worked for and reference check vendors.
    Your information (i.e. name) may be disclosed to your previous workplaces and reference check vendors.
  • Service providers.
    We may disclose your information to companies that provide Services on our behalf. These entities cannot use your information for purposes other than providing Services on our behalf.
  • Other parties when required by law or as necessary to protect our rights.
    There may be instances where we disclose your information to other parties:
    • - to comply with legal obligations or legally binding disclosure orders (such as a search warrant or other court/regulatory order);
    • - to verify or ensure compliance with the terms and policies governing our Services; and
    • - to protect the rights, property, or safety of us or any of our business partners or customers.
  • Other parties in connection with corporate transactions.
    We may disclose your information to a third party as part of a merger or transfer, or in the event of a bankruptcy.
  • Other parties with your consent or at your direction.
    In addition to the disclosures described in this Privacy Policy, we may disclose information about you to third parties when you consent to or request such disclosure.
Your Rights

To the extent permitted under applicable law(s), you may ask us to return, destroy, or correct any inaccuracies regarding your personal information. You may also ask us to restrict or limit our use of your personal information unless such restriction or limitation prevents us from complying with applicable law(s) or meeting a legal obligation.

However, your rights above may be limited in cases where your request would disclose personal information of a third party or where such a request would infringe the rights of a third party (including our rights) or if you ask us to delete information which we are required by law to preserve or have legitimate interests in retaining. Other relevant exemptions may exist under the GDPR and national laws. We will inform you of the relevant exemptions when responding to your request. To make such a request concerning your rights set forth herein, please refer to the Contact Us section below.

International Transfer of Information

We are a company based in Korea, and your use of our Website and Services will involve the transfer, storage, and processing of your personal information in Korea. Please note that the information protection laws and other applicable laws of countries outside the European Economic Area (“EEA”), to which your information may be transferred, might not be as comprehensive as those in your country. We will take appropriate measures, in compliance with applicable law, to ensure that your personal information remains protected. Such measures include the use of EU Standard Contractual Clauses to safeguard the transfer of information outside of the EEA or other methods. For more information, please contact us at privacy.bio@samsung.com.

Data Retention

We will retain your personal information for a reasonable period of time that enables us to communicate with you, to provide you with Services, to maintain business records for audit purposes, to meet recordkeeping requirements under applicable law(s), to defend or bring any legal claims and to deal with any queries or complaints you may have.

Keeping Your Information Secure

We have put in place reasonable measures to safeguard the information we collect in connection with the Services. However, please note that although reasonable steps will be taken to protect your information, no website, internet transmission, computer system or wireless connection is 100% secure from any and all potential threats.

Personal Information – Children under the age of 13

The Services are designed for general audience and are not intended or directed to children.

For US Residents Only

In connection with the Services, we will not knowingly solicit or collect personal information from children under the age of 13. In the event we do collect such personal information inadvertently or unknowingly and we later learn about it, we will promptly delete such information. If you believe that children under the age of 13 may have provided personal information to us, please contact us using the Contact Us section of this Privacy Policy.

If You are an individual resident in the EU

We process your personal information on the legal grounds that the processing is :

  • Necessary for the performance of contractual obligation(s) between you and us, for example if we’re providing service(s) that you have requested;
  • Necessary for compliance with our legal obligations;
  • Necessary for our legitimate interests, such as preparing our communications to you and continuing to develop and improve our services; or
  • With your consent or at your direction.

If you do not provide certain information to us, we may, in some circumstances, be unable to comply with our obligations or provide you with the services that you request. We will inform you of the implications of not providing certain information.

As set forth in the “Your rights” section, you are entitled, in accordance with applicable law, to object to or request restriction of processing your personal information, and to request access to, correction of, or deletion of your personal information. When we use your information on the basis of your consent, you have the right to withdraw such a consent at any time. Any requests should be submitted in writing to the address listed below in the “Contact Us” section. You also have the right to file a complaint with data protection authorities.

Contact Us

If you have any questions about this Privacy Policy, please contact us using the details below.

- Contact : 032-455-9829

- Email : privacy.bio@samsung.com

Changes to this Privacy Policy

We may update this Privacy Policy from time to time. When we update the Privacy Policy, we will revise the “Effective Date” above and post the new Privacy Policy with a new date. We recommend that you review the Privacy Policy each time you visit our Website to stay informed of our most current practices and policies.

close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION